Extended Data Fig. 6: Tumor suppression and effector cells of Crunch in melanoma.
From: Phagocytic clearance of targeted cells with a synthetic ligand
a, Strategy for Crunch treatment in tumor engraftment. GFPm+ B16.F10 melanoma cells (5 ×105) were injected subcutaneously into WT mice. Saline or 100 µg GFPNb-Crunch were administered on Day 1, 8, and 15. b-c, Tumor growth following Crunch treatment. Tumor volumes were measured every three days and calculated as V = πLW²/6 (V: volume, L: long diameter, W: short diameter). The graph shows the mean tumor volume (b) and individual tumor volumes (c) for each mouse (Saline n = 6, Crunch n = 4 mice). Significant differences were observed on Day 12 (P = 0.030), Day 15 (P = 0.024), and Day 18 (P = 0.021). Data are shown as mean ± S.D. Statistical analysis was performed using Student’s unpaired t test. *P < 0.05 d-e, t-SNE analysis of non-malignant cells in the tumor microenvironment (TME) of human melanoma. Single-cell data (4857 cells, GSE115978, non-malignant cells) were clustered into various cell types: B cells, T cells, cancer-associated fibroblasts (CAF), endothelial cells, macrophages, NK cells, CD4+ T cells, and CD8+ T cells (d). MerTK expression was assessed in each cell type (e). f-h, MerTK expression in the TME of B16.F10 xenograft tumors. B16.F10 cells (5 ×105) were injected into C57BL/6 mice, and primary tumors were extracted at Day 9. Single-cell suspensions were stained for MerTK, CD45, CD11b, Ly6C, Ly6G, and F4/80 antibodies, and analyzed by flow cytometry. Singlet cells population plot was shown with or without an anti-MerTK antibody (f). MerTK expression in each cell population is shown (g). CD45 + CD11b+ cells and CD45 + CD11b+ MerTK+ cells, were analyzed by Ly6C/F4/80 or Ly6C/Ly6G expression (h). Gating strategy is shown in Supplementary Fig. 10.
